Engimmune Therapeutics

Executive Summary

Engimmune Therapeutics is a Swiss biotech company pioneering next-generation soluble T cell receptor (TCR) therapies for solid tumors and immune-mediated diseases. Founded in 2018 and headquartered in Basel, the company leverages a proprietary AI-guided protein engineering platform to develop highly potent, stable, and safe 'off-the-shelf' soluble TCR drugs. This approach aims to unlock a vast array of intracellular targets that are currently inaccessible to conventional antibody-based therapies, potentially transforming treatment paradigms in oncology and autoimmune disorders. Engimmune's technology addresses key limitations of existing TCR therapies, including stability, manufacturability, and immunogenicity, positioning it as a leader in the emerging field of soluble TCR biologics. Currently in the pre-clinical stage, Engimmune is advancing its lead programs toward IND-enabling studies. The company is actively pursuing a multi-product strategy, targeting both validated and novel antigens with high therapeutic potential. With a strong intellectual property portfolio and a seasoned management team, Engimmune is well-positioned to attract partnerships and financing to accelerate clinical development. Its innovative platform has the potential to expand the druggable proteome significantly, offering hope for patients with difficult-to-treat cancers and autoimmune conditions. The near-term focus is on completing preclinical validation and initiating first-in-human studies within the next 12-18 months.

Upcoming Catalysts (preview)

• Q2 2027Completion of IND-enabling studies and submission of IND/CTA for lead program70% success
• Q4 2026Presentation of preclinical proof-of-concept data at major medical conference (e.g., AACR or SITC)85% success
• Q1 2027Series B financing round to fund clinical development60% success